The biotech market has seen a flurry of activities related to insurance provider, Humana Inc. (HUM). Firstly, Pullen Investment Management LLC has acquired 1,522 shares, while a partnership with Mercy led to the expansion of elderly care through 65 Prime+ Clinics. Humana’s health ventures with athenahealth and Your Health have aimed at mitigating gaps in care while simultaneously reducing clinicians’ administrative burden. Humana has also partnered with Monogram Health to enhance kidney care.
However, Humana has faced legal challenges, with investigations launched by Edelson Lechtzin LLP, and concerns raised over its Medicare Advantage billing practices. The company’s shares have fluctuated, with Jefferies and Barclays reducing price targets and analysts from Wall Street Zen cutting the rating to Hold. Despite these challenges, Humana’s strategic shifts and cost-cutting measures in the Q1 earnings have buoyed their stock value. Conversely, Humana’s expectations of a membership drop and consequently, reduced profit projections for 2025 have been points of concern.
Humana has been advocating for the limiting of Medicare Advantage home visits and has also faced increased scrutiny from regulators on its Medicare practices. Despite the declines, Humana has revealed an intention to reaffirm its 2025 EPS Outlook.
Humana HUM News Analytics from Wed, 02 Oct 2024 07:00:00 GMT to Sat, 14 Jun 2025 10:43:24 GMT - Rating -3 - Innovation 4 - Information 6 - Rumor 2
